Citation: Ei. Ette et al., BALANCED DESIGNS IN LONGITUDINAL POPULATION PHARMACOKINETIC STUDIES, Journal of clinical pharmacology, 38(5), 1998, pp. 417-423
Citation: Ei. Ette et al., IGNORABILITY AND PARAMETER-ESTIMATION IN LONGITUDINAL PHARMACOKINETICSTUDIES, Journal of clinical pharmacology, 38(3), 1998, pp. 221-226
Authors:
GRAUMLICH JF
LUDDEN TM
CONRYCANTILENA C
CANTILENA LR
WANG YH
LEVINE M
Citation: Jf. Graumlich et al., PHARMACOKINETIC MODEL OF ASCORBIC-ACID IN HEALTHY MALE-VOLUNTEERS DURING DEPLETION AND REPLETION, Pharmaceutical research, 14(9), 1997, pp. 1133-1139
Citation: Ml. Mcfadyen et al., KETOTIFEN PHARMACOKINETICS IN CHILDREN WITH ATOPIC PERENNIAL ASTHMA, European Journal of Clinical Pharmacology, 52(5), 1997, pp. 383-386
Authors:
LUDDEN LK
LUDDEN TM
COLLINS JM
PENTIKIS HS
STRONG JM
Citation: Lk. Ludden et al., EFFECT OF ALBUMIN ON THE ESTIMATION, IN-VITRO, OF PHENYTOIN V-MAX ANDK-M VALUES - IMPLICATIONS FOR CLINICAL CORRELATION, The Journal of pharmacology and experimental therapeutics, 282(1), 1997, pp. 391-396
Citation: Hs. Pentikis et al., BIOEQUIVALENCE - INDIVIDUAL AND POPULATION COMPARTMENTAL MODELING COMPARED TO THE NONCOMPARTMENTAL APPROACH, Pharmaceutical research, 13(7), 1996, pp. 1116-1121
Citation: H. Sun et al., ON THE RECORDING OF SAMPLE TIMES AND PARAMETER-ESTIMATION FROM REPEATED-MEASURES PHARMACOKINETIC DATA, Journal of pharmacokinetics and biopharmaceutics, 24(6), 1996, pp. 637-650
Citation: H. Surr et al., A PHARMACOKMETIC PHARMACODYNAMIC (PK PD) MODEL DESCRIBING THE COMBINED EFFECTS OF FEEDBACK, REGULATION AND COMPLEXATION (FRC) PROCESS/, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 4-4
Authors:
LUDDEN LK
PENTIKIS HS
LUDDEN TM
COLLINS JM
STRONG JM
Citation: Lk. Ludden et al., THE ADDITION OF ALBUMIN, IN-VITRO, YIELDS MEANINGFUL FREE DRUG KM VALUES FOR PHENYTOIN METABOLISM, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 45-45
Citation: Ei. Ette et Tm. Ludden, POPULATION PHARMACOKINETIC MODELING - THE IMPORTANCE OF INFORMATIVE GRAPHICS, Pharmaceutical research, 12(12), 1995, pp. 1845-1855
Citation: Aa. Eltahtawy et al., EVALUATION OF BIOEQUIVALENCE OF HIGHLY VARIABLE DRUGS USING MONTE-CARLO SIMULATIONS .1. ESTIMATION OF RATE OF ABSORPTION FOR SINGLE AND MULTIPLE-DOSE TRIALS USING CMAX, Pharmaceutical research, 12(11), 1995, pp. 1634-1641
Citation: Tm. Ludden et al., PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING AS A TOOL FOR DRUG DEVELOPMENT - COMMENTARY, Journal of pharmacokinetics and biopharmaceutics, 23(2), 1995, pp. 231-235
Citation: Hy. Abdallah et Tm. Ludden, A SPREADSHEET PROGRAM FOR SIMULATION OF BIOEQUIVALENCE AND BIOAVAILABILITY STUDIES, Computers in biology and medicine, 25(3), 1995, pp. 349-354
Citation: Rs. Pradhan et al., POPULATION PHARMACOKINETICS OF IV AMIODARONE - RAPID SCREENING OF COVARIATES, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 156-156
Citation: Aa. Eltahtawy et al., COMPARISON OF SINGLE AND MULTIPLE-DOSE PHARMACOKINETICS USING CLINICAL BIOEQUIVALENCE DATA AND MONTE-CARLO SIMULATIONS, Pharmaceutical research, 11(9), 1994, pp. 1330-1336
Citation: Tm. Ludden et al., COMPARISON OF THE AKAIKE INFORMATION CRITERION, THE SCHWARZ CRITERIONAND THE F-TEST AS GUIDES TO MODEL SELECTION, Journal of pharmacokinetics and biopharmaceutics, 22(5), 1994, pp. 431-445
Authors:
GRAUMLICH JF
LUDDEN TM
CANTILENA CC
LEVINE M
WELCH RW
WANG Y
DHARIWAL K
PARK J
WASHKO P
LAZAREV A
KING J
CANTILENA LR
Citation: Jf. Graumlich et al., PHARMACOKINETIC MODEL OF ASCORBIC-ACID IN DEPLETION AND REPLETION, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 200-200
Authors:
JOHNSON FE
TOLMAN KC
FARR SA
DAVIS PJ
LUDDEN TM
ROY TK
RAJU PI
Citation: Fe. Johnson et al., SERUM LEVELS OF PENTOXIFYLLINE AND ITS METABOLITES IN NON-TUMOR-BEARING MICE AFTER CHRONIC ORAL PENTOXIFYLLINE ADMINISTRATION, Journal of medicine, 24(2-3), 1993, pp. 131-143